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Abstract
We have recently shown that silencing of the brain/islet specific c-Jun N-terminal Kinase3 (JNK3) isoform enhances both
basal and cytokine-induced beta-cell apoptosis, whereas silencing of JNK1 or JNK2 has opposite effects. While it is known
that JNK1 or JNK2 may promote apoptosis by inhibiting the activity of the pro-survival Akt pathway, the effect of JNK3 on
Akt has not been documented. This study aims to determine the involvement of individual JNKs and specifically JNK3 in the
regulation of the Akt signaling pathway in insulin-secreting cells. JNK3 silencing strongly decreases Insulin Receptor
Substrate 2 (IRS2) protein expression, and blocks Akt2 but not Akt1 activation by insulin, while the silencing of JNK1 or JNK2
activates both Akt1 and Akt2. Concomitantly, the silencing of JNK1 or JNK2, but not of JNK3, potently phosphorylates the
glycogen synthase kinase3 (GSK3b). JNK3 silencing also decreases the activity of the transcription factor Forkhead BoxO3A
(FoxO3A) that is known to control IRS2 expression, in addition to increasing c-Jun levels that are known to inhibit insulin
gene expression. In conclusion, we propose that JNK1/2 on one hand and JNK3 on the other hand, have opposite effects on
insulin-signaling in insulin-secreting cells; JNK3 protects beta-cells from apoptosis and dysfunction mainly through
maintenance of a normal IRS2 to Akt2 signaling pathway. It seems that JNK3 mediates its effects mainly at the
transcriptional level, while JNK1 or JNK2 appear to mediate their pro-apoptotic effect in the cytoplasm.
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Introduction
Sustained pancreatic beta-cell death, which mainly occurs by
apoptosis, ultimately leads to diabetes mellitus [1–3]. Apoptosis
follows an autoimmune process called insulitis that involves
secretion of a number of pro-inflammatory cytokines by activated
inflammatory cells including interleunkin-1beta (IL-1b), tumor
necrosis factor alpha (TNF-a) and interferon gamma (IFNc) [4–6].
It has been shown that exposure of beta-cells to these cytokines is
sufficient to induce apoptosis [3,4].
The c-Jun N-terminal Kinases (JNKs), also known as stress-
activated protein kinases (SAPKs), are potently activated by pro-
inflammatory cytokines and have been involved in cytokine-
mediated beta-cell apoptosis [7–9]. Three JNK isoforms have been
identified: JNK1, JNK2, and JNK3. JNK1 and JNK2 are
ubiquitously expressed, while JNK3 was found to be restricted to
the brain and testis [10,11]; we however recently described high
expression and functional role of this isoform in pancreatic islet
cells [12]. Despite their high structural homology, the JNK
isoforms have distinct biological functions. Genetic disruption of
Jnk1 is associated with insulin resistance and obesity [13], while
Jnk2 disruption partially protects Non-Obese Diabetic (NOD)
mice from destructive insulitis [14]. While Jnk3 knockout animals
have not been studied for metabolic disorders, we provided
evidence that JNK3 is protective against cytokine-induced
apoptosis in an insulin-secreting cell line [12].
Several studies have shown that activation of JNK1 or JNK2
leads to inhibition of the pro-survival Akt (also called protein
kinase B (PKB)) pathway and sensitizes pancreatic beta-cells to
death [15–18]. Conversely, JNK blockade enhances Akt signaling
and improves beta-cell survival [17]. It therefore seems that the
JNK and Akt signaling pathways might cross-talk to determine the
fate and function of the beta-cells in response to extracellular
stimuli.
Three Akt (Akt1, Akt2, and Akt3) isoforms have been
described, and they all share structural similarities; they however
differ in their expression profiles and functions [19–21]. Akt1 is
the major isoform ubiquitously expressed, while Akt2 is less
abundant, except in insulin responsive tissues [22,23]. The third
isoform Akt3 has been described mostly in brain, testis and
beta-cells [24]. Emerging evidence indicates that Akt controls
beta-cell proliferation, survival, insulin synthesis and secretion
[16,25,26]. Akt1-deficient mice have normal carbohydrate
metabolism but show growth defects [20,27]. Importantly,
Akt2-deficient mice develop mild to severe diabetes with high
beta-cell loss [28,29]. It has been postulated that this high beta-
cell loss results from an increased propensity of Akt2-null cells to
die from apoptotic stimuli.
AmajorregulatorofAktsignaling ininsulin-secretingcells is insulin
itself that binds to the insulin receptor (IR) before recruiting the
Insulin Receptor Substrates (IRSs) [30–32]. In turns, the IRSs
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mediate phosphoinositide3-kinase (PI3-K) activation and subse-
quent generation of phosphatidylinositol phosphate3 (PIP3) that
bindsandrecruitsAkt to theplasmamembrane[33].Fullactivationof
Akt involves phosphorylation of both Threonine 308 (Thr308) and
Serine 473 (Ser473) residues by different protein kinases [34,35].
Akt activity is negatively regulated by two mechanisms:
indirectly by dephosphorylation of the lipid PIP3 product by the
protein phosphatase PTEN (phosphatase and tensin homolog)
[36,37], and by direct dephosphorylation of Akt by specific
phosphatases, the Pleckstrin homology and leucine rich repeat
protein phosphatases (PHLPPs) [38]. PTEN negatively regulates
the intracellular levels of PIP3 in cells and functions as a tumor
suppressor by regulating Akt signaling pathway [39]. The PHLPPs
is a recently identified group of two protein phosphatases,
PHLPP1 and PHLPP2 that inhibit several protein kinases
including Akt. Both PHLPP1 and PHLPP2 have been shown to
directly dephosphorylate and therefore inactivate Akt isoforms at
one of two critical phosphorylation sites required for their
activation [40]. PHLPP2 is able to dephosphorylate Akt1 at
Ser473 whereas PHLPP1 preferentially dephosphorylates Akt2
[38,40].
Akt acts through a wide array of downstream protein substrates
involved in apoptosis, mitogenesis, cell proliferation and survival.
Among the downstream targets of Akt are the Ser/Thr glycogen
synthase kinase3b (GSK3b), and the members of the Forkhead
BoxO (FoxO) family of transcription factors [41,42]. Akt mediates
cell survival through the phosphorylation of GSK3b which has
been proposed as a promising target for beta-cell protection [43].
The phosphorylation of GSK3b by Akt (inhibits kinase activity)
positively affects beta-cell mass and function while its dephos-
phorylation (kinase activation) enhances beta-cell death [44,45].
The transcription factors FoxO consist of three members; FoxO1,
FoxO3A, and FoxO4, which are all inactivated by Akt [46]. In
pancreatic beta-cells, FoxO1 is predominantly expressed while
FoxO3A is expressed at a lower level. Activation of Akt signaling
mediates the phosphorylation of the FoxO factors which leads to
the nuclear exclusion and then inhibition of the FoxO transcrip-
tional program [47,48]. In pancreatic beta-cells, it has been shown
that FoxO3A specifically controls basal expression of IRS2; this
participates to the maintenance of a normal beta-cell mass and
function [49].
We have recently shown that JNK3, in contrast to JNK1 and
JNK2, has a protective effect in pancreatic beta-cells [12]. We here
propose that JNK3 mediates at least partly its protective effect
against cytokines through functional preservation of the anti-
apoptotic IRS2/Akt2 signaling pathway.
Methods
Cell Culture
The INS-1E cell line [50] was grown in RPMI-1640 medium
(Invitrogen, Basel, Switzerland) containing 10% (vol/vol) heat-
inactivated fetal bovine serum (FBS) supplemented with 1 mmol/l
sodium pyruvate, 10 mmol/l HEPES (pH 7.6), and 50 mmol/l b-
mercaptoethanol. Cells were incubated in a humidified atmo-
sphere of 5% CO2 at 37uC.
Cell Transfection and Treatments
Cells were incubated overnight at a density of 0.66106 in six-
well plates with antibiotic free medium. Small interfering RNA
(siRNA) duplexes targeting Jnk1, Jnk2, Jnk3, or the green
fluorescent protein (GFP) were mixed with LipofectamineTM2000
reagent according to the manufacturer’s instructions (Invitrogen,
Basel, Switzerland). siRNA-Lipofectamine complexes were added
to the cells and incubated for 2 days. Cells were then treated with
a cocktail of cytokines: recombinant rat IL-1b (10 ng/ml, R&D
systems, Minneapolis, MN, USA), TNF-a (10 ng/ml, Sigma-
Aldrich, Switzerland), and IFNc (100 ng/ml, Sigma-Aldrich,
Switzerland) at the indicated times (see legend figures). For
experiments aimed at characterizing insulin-signaling, cells were
starved (serum-free) overnight in media supplemented with
2 mmol/l glucose. Cells were then stimulated with recombinant
human insulin (100 nmol/l, Sigma-Aldrich, Switzerland) for 30
minutes and processed for protein extract preparations.
Western Blotting
Cells were lysed in cold lysis buffer [51] and the protein extracts
were recovered by centrifugation (at 14,000 rpm for 30 minutes) at
4uC. Equal quantities of total protein lysates were resolved by
SDS-PAGE and electroblotted onto nitrocellulose membranes.
The blots were probed overnight with primary antibodies against:
JNK1, JNK2, JNK3, Akts, PTEN, IRS1, IRS2, FoxO3A,
phospho-GSK3b, phospho-Akt1, phospho-Akt2; phospho-FoxO
(1:1,000; Cell Signaling Technology, MA, USA), PHLPP1
(1:1,000 Millipore) and PHLPP2 (1:200; Biotechnology, Santa
Cruz, CA, USA). Equal protein loading was ascertained by
blotting membranes against tubulin (1:5,000; Sigma-Aldrich,
Switzerland). Anti-rabbit or anti-mouse horseradish peroxidase-
conjugated secondary antibodies were used to detect proteins with
an enhanced chemiluminescence (ECL) reaction system (Pierce).
RNA Preparation and Northern Blot Analysis
Total RNA was extracted using a commercial kit from Qiagen
(RNeasy Mini-kit; QIAGEN AG, Basel, Switzerland). 1 mg of the
prepared RNA was used for a single-strand cDNA synthesis by the
‘‘Transcriptor’’ high fidelity reverse transcriptase enzyme and
performed according to the detailed instructions provided by the
manufacturer (Transcriptor High Fidelity cDNA Synthesis Kit,
Roche Diagnostics AG, Switzerland). Jnk1, Jnk2, Jnk3, and tubulin
mRNA expressions were quantified using the standard LightCycler
480 SYBR Green I Master procedure according to the manufac-
turer’s instructions (LightCycler, 480 SYBRGreen IMaster, Roche
Diagnostics AG, Switzerland). The sequences of the Jnk1, Jnk2, Jnk3
or tubulin primers were previously described [12].
Figure 1. Efficiencies of the siRNAs. (A) INS-1E cells were transiently transfected with Jnk1 (si1), Jnk2 (si2), and Jnk3 (si3) siRNAs for 2 days and
total RNAs were prepared and used in quantitative real-time PCR experiments. GFP siRNA (siFGP) was used as a transfection control. Data were
normalized to tubulin, and represent the means6SD of three independent experiments performed in triplicates. ***p,0.001 (B) JNK protein
knockdowns were evaluated by western blotting using specific antibodies against JNK1, JNK2, and JNK3 as described previously (12). Densitometric
values for the JNKs bands normalized to tubulin were shown below the blot; untreated cells (control) values were set to 1. Data are the means6SD of
four independent experiments repeated in duplicates. ***p,0.001 (C,D) Cells transfected with Jnk (si1, si2, si3), or GFP (siGFP) siRNAs were exposed
to (C) cytokines (4 hrs) or (D) overnight starved before being treated with insulin (309). IRS2 protein expression levels were determined by western
blot analysis. Equal protein loading was assessed by blotting membranes with an antibody against tubulin. (E) similar data as in (C), but showing IRS1
protein expression. (F) Graphical presentations summarizing the effects of the different Jnk siRNAs vs siGFP in stimulated conditions; control values
are set to 1. Data are the means6SD of four independent experiments repeated in duplicates. **p,0.01 for cyto-Mix-siGFP vs cyto-Mix-si1 or cyto-
Mix-si2 for (C), **p,0.01 for siGFP-Ins vs si3-Ins, and **p,0.01 for cyto-Mix-siGFP vs cyto-Mix-si1 and *p,0.05 for cyto-Mix-siGFP vs cyto-Mix-si2 (E).
doi:10.1371/journal.pone.0035997.g001
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Data Analysis
All experiments were performed a minimum of three times in
duplicates (i.e. n = 3–5). Data are shown as means6SD. Statistical
significances were calculated either by ANOVA or two-tailed t test
for single comparisons.
Results
JNK3 Controls IRS2 Protein Content in Insulin-secreting
Cells
IRS2 promotes beta-cell growth and survival and we have
shown that cells with reduced JNK3 expression undergo
spontaneous apoptosis [12]. We therefore wanted to determine
whether JNK3 might control IRS2 in insulin-secreting cells. To
this end, INS-1E cells were transfected with siRNAs targeting
selectively each one of the three individual Jnks and RNA and
protein extracts were prepared for RT-PCR and western blot
analysis. Jnk1 siRNA significantly reduced Jnk1 (77% decrease)
without interfering with Jnk2 or Jnk3 mRNA expression. Similarly,
Jnk2 (91.5% decrease), and Jnk3 (76% decrease) siRNAs
specifically decreased expression of their respective mRNAs
(Fig.1A). The GFP siRNA used as a transfection control has no
significant effect on the mRNA expressions on any of the three Jnk
isoforms (Fig.1A). The different Jnk siRNAs were also tested at the
protein level by western blot analysis using JNK isoform-specific
antibodies (see our previous paper for a detailed analysis of the
specificity of the antibodies used (12)). Jnk1, Jnk2, and Jnk3 siRNAs
reduced the protein expression of their respective JNK isoform by
71%, 83% and 66%, respectively (Fig.1B).
As shown in Figures 1C to D, JNK3 silencing markedly
decreases IRS2 protein content, especially in presence of cytokines
(Fig.1C), or following over-night starvation of cells (this stress
results in activation of JNKs that reach similar levels to those
obtained with the cytokines-mix used in this study, data not shown)
(Fig.1D); in contrast, JNK1 silencing enhances IRS2 content
(Fig.1C). We also observed a comparatively slighter decrease of
IRS1 expression, but this did not reach statistical significance
(Fig.1E). However, silencing JNK1 positively regulates IRS1
(Fig.1E/F).
JNK3 Specifically Regulates Akt2 Phosphorylation in
Insulin-secreting Cells
As for Akt1, the Akt2 isoform regulates beta-cell growth and
survival; however, Akt2 distinctively controls glucose metabolism
as Akt2-deficient mice develop diabetes [29]. Accordingly, we
aimed to examine whether individual JNK silencing (specifically
JNK3) could affect the activation profile of Akt2 or Akt1. As
expected from the loss of IRS2 expression, decreased JNK3
efficiently inhibited insulin-induced Akt2 activation and caused
disruption of insulin signaling (Fig.2). Western blot analysis
indicates that JNK3 knockdown strongly inhibits Akt2ser474
phosphorylation (hence its activation) in cytokine-treated INS-1E
cells (Fig.2A). Increase in Akt2 phosphorylation levels are evident
following JNK1 or JNK2 knockdown in insulin or cytokine-treated
cells (Fig.2A/B). In all tested condition, there are no changes in the
protein expression levels of total Akts (Fig.2A/B).
JNK1 or JNK2 Silencing Modulates the Phosphorylation
of Akt1 in Insulin-secreting Cells
We next examined whether individual JNKs could distinctly
interfere with Akt1 phosphorylation in response to insulin and
cytokines stimuli. Our data show that JNK1 or JNK2 silencing
enhanced Akt1ser473 phosphorylation at basal state or following
cytokines (Fig.2C) or overnight starvation followed by insulin
(Fig.2D) treatment. However, no major effect is observed in cells
with reduced JNK3 (Fig.2C/D/E). The protein expression levels
of total Akts remain unchanged in all condition tested (Fig.2).
JNK Silencing Modulates the Activity of the Downstream
Substrates of Insulin Signaling GSK3b and FoxO in
Cytokine-treated Cells
It has been shown that Akt signaling acts on many pro-apoptotic
targets in beta-cells, including the kinase GSK3b [44] and the
transcription factors FoxO [46]. We first determined the activity of
GSK3b following JNK silencing. Western blot analysis indicates
that JNK1 or JNK2 silencing enhanced the phosphorylation of the
GSK3b kinase (reduced activity) at both basal state and after
cytokines treatment (Fig.3A). In contrast, JNK3 silencing has no
effect on GSK3b activity compared to control conditions (Fig.3A/
C).
In beta-cells, the PI3K-Akt pathway is a major upstream
modulator of the activity of the transcription factors FoxO, which
blocks their function by phosphorylation [46]. Recently, it has also
been shown that FoxO3A controls IRS2 transcription in beta-cells
[49]. To gain further insights into the regulatory mechanisms that
may control the observed shutting-off of the IRS2 signaling
pathway when JNK3 is silenced, we investigated the expression
levels and phosphorylation status of the transcription factor
FoxO3A after cytokine exposure. Western blot experiments show
that JNK3 silencing is most efficient at enhancing the phosphor-
ylation of FoxO3A (therefore inhibiting its activity) (Fig.3B/C).
JNK3 does not Control the Activity of the Phosphatases
PTEN and PHLPPs in Insulin-secreting Cells
We also studied the expression levels of the phosphatases PTEN
(Fig.4A) and PHLPP1/2 Fig.4A/B) that are known to regulate
Akts activations. None of the parameters studied appeared to be
influenced by JNK3 silencing in the INS-1E cell-line exposed to
cytokines.
Discussion
Pro-inflammatory cytokines have been shown to mediate beta-
cell apoptosis through a mechanism that appears to involve the
activation of the JNKs [8,9]. Three JNK isoforms (JNK1, JNK2
and JNK3) have been described which are all expressed in insulin-
secreting cells, and we have shown that in contrast to JNK1 and
JNK2 whose activation is clearly pro-apoptotic, JNK3 has an
unexpected role in preserving beta-cells against a number of
different insults including cytokines [12]. We had postulated that
these differential effects might be linked to the different sub-
cellular localization of these isoforms: whereas JNK1 and JNK2
are mainly cytosolic, JNK3 is exclusively nuclear [12].
We here show that silencing of JNK3 leads to a marked
reduction in IRS2 expression and signaling. The mechanism
behind this regulation remains uncharacterized (but see below),
but it implies that JNK3 is essential to preserve IRS2 expression,
especially when cytokines are present (Fig.1). In contrast, silencing
of JNK1 or JNK2 leads to an increased Akt signaling (Fig.2), an
effect that is certainly linked to a decreased Ser/Thr phosphor-
ylation of the IRS proteins by the lowered content of the cytosolic
JNKs in these conditions [18,52] (and hence an improved ability of
the non-phosphorylated IRSs to bind to the IR). Conversely,
JNK3, which is exclusively nuclear, is not expected to have direct
access to the IRS proteins, and may only regulate them either at
the transcriptional level or indirectly.
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Figure 2. Effect of JNK silencing on Akts phosphorylation. Cells were transfected with Jnks (si1, si2, si3) or GFP (siGFP) siRNAs for 2 days.
Transfected cells were (A,C) treated with cytokines (4 hrs) or (B,D) overnight starved then treated with insulin (309). Protein extracts were used for
western blotting with anti-phospho-Akt2 (p-Akt2474) and anti-Akts antibodies (A,B), or anti-phospho-Akt1 (p-Akt1473) and anti-Akts antibodies (C, D).
Equal protein loading was assessed by blotting membranes with an antibody against tubulin. (E) Graphical presentations summarizing the effects of
the different Jnk siRNAs vs siGFP in stimulated conditions; control values are further set to 1. The data are the means6SD of three independent
experiments. Significant differences were obtained for p-Akt2/p-Akt1 in si1 and si2 vs p-Akt2/p-Akt1 (siGFP) in cytokines (*P,0.05) or starved-insulin
treated cells (*P,0.05 or **p,0.01).
doi:10.1371/journal.pone.0035997.g002
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Figure 3. Effect of JNK silencing on downstream substrates of insulin signaling. Cells were transfected with Jnks (si1, si2, si3) or GFP (siGFP)
siRNAs for 2 days and then exposed to cytokines (4 hrs). Western blot analysis was performed to determine (A) phospho-GSK3b or (B) phospho-
FoxO3A and FoxO3A. Equal protein loading was assessed by blotting membranes with an antibody against tubulin. (C) Graphical presentations
summarizing the effects of the different Jnk siRNAs vs siGFP in cytokine-treated cells; control values are set to 1. The data are the means6SD of three
independent experiments. (**P,0.01) for cyto-Mix-siGFP vs cyto-Mix-si1, and cyto-Mix-si2. (***p,0.001) for cyto-Mix-siGFP vs cyto-Mix-si3. Significant
differences were obtained for phospho-GSK3b in si1, si2, and si3 vs siGFP (***p,0.001).
doi:10.1371/journal.pone.0035997.g003
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The role of IRS2 in beta-cell growth and survival has been well
studied in vitro using primary pancreatic islets, and in vivo. Mice
with full deletion of Irs2 show peripheral insulin resistance and islet
cell loss that progress to diabetes [53]. Moreover, mice with
deletion of the Irs2 gene specifically into pancreatic beta-cells
develop glucose intolerance, and reduced beta-cell mass [54].
Therefore, IRS2 which appears to regulate peripheral response to
insulin action also controls pancreatic beta-cell mass [55].
Conversely, signal transduction via IRS1 is less critical for beta-
cell growth and survival as mice lacking Irs1 did not become
diabetic because of an adequate expansion of beta cell mass in
presence of IRS2 [53]. In our conditions, reducing JNK3 did not
show a significant decrease of IRS1 protein which indicates
specific regulation of IRS2 by the JNK3 isoform. In contrast, we
observed a slight increase in IRS1 expression levels when silencing
JNK1.
As expected from the loss of IRS2 expression, our study shows
that JNK3 suppression further inhibits Akt2 phosphorylation
(phospho-Ser474) by insulin. Akt2 (which lays immediately
downstream of IRS2 in the insulin signaling cascade) has been
shown to control beta-cell growth and survival as well; it
distinctively regulates glucose metabolism as Akt2-null mice
develop severe diabetes with high loss of beta-cell mass,
a phenotype clearly similar to the one observed with Irs2-null
mice [28,29,53]. Hence, we may link the protective action of
JNK3 in insulin secreting cells to its preservative role on the IRS2/
Akt2 signaling pathway.
Akts may affect survival directly by regulating the activity (post-
translational regulation) of their target substrates or indirectly by
eliciting gene expression (transcriptional regulation). In beta-cells,
GSK3b is a direct substrate of the PI3K-Akt pathway and its down
regulation (increased phosphorylation) can protect cells from death
[44,56,57].
Akts also modulate (by phosphorylation) the activity of the
FoxO1 and FoxO3A transcription factors and block their
translocation into the nucleus [46]. In beta-cells, the exact role
of the FoxO proteins is not fully characterized [58]. It has been
shown that decreasing levels of FoxO1 restore Pancreatic and
Duodenal homeobox1 (PDX1) expression and nuclear localization
and rescue the loss of beta-cells in Irs2-deficient mice, suggesting
that FoxO1 and PDX1 can mediate proliferative signals induced
by Akts [47,59]. Alternatively FoxO3A but not FoxO1 has been
shown to regulate Irs2 expression [49]. In our conditions, JNKs
silencing reduced FoxO3A activity (enhanced phosphorylation)
particularly after JNK3 silencing. On the other hand, silencing
JNK1 or JNK2 decreased FoxO1 activity, while its activity
increased when JNK3 is silenced (data not shown). Activated
FoxO1 may trigger the transcriptional machinery to induce the
expression of relevant genes to inhibit beta-cell survival [47]. The
decrease in FoxO3A activity while Akts activities are low (because
Figure 4. Expression of different regulators of the insulin-signaling pathway. Protein expression levels of the phosphatases (A) PTEN,
PHLPP2, and (B) PHLPP1 were studied in conditions similar to those described in Figs.1 to 3. No relevant alterations of the protein expression levels in
any condition could be demonstrated.
doi:10.1371/journal.pone.0035997.g004
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of reduced JNK3 in presence of cytokines) may participate to the
observed defect in IRS2 expression.
We have published previously that silencing of JNK3 aggravates
the down-regulation of insulin mRNA levels caused by cytokines.
Earlier studies have indicated that stress-mediated activation and
stabilization of c-Jun suppresses insulin gene transcription by
affecting the transactivation potential of the E2A gene products on
the insulin promoter [60]. We have shown that JNK3, but not
JNK1 or JNK2, silencing potently increases c-Jun levels, an effect
that is in line with the specific nuclear localization of the kinase; it
is therefore conceivable that the decrease in insulin mRNA
expression observed in conditions of low JNK3 is mediated
through an increase in c-Jun expression and/or stability [12]. In
contrast, JNK1 and JNK2 with their mainly cytosolic localization
do affect neither c-Jun levels nor insulin expression. With respect
to IRS2 expression, it is known that both Irs2 mRNA and protein
are short-lived (with mRNA and protein half-lives of 90 min and
2 h, respectively), and thus IRS2 expression appears to be mainly
regulated at the transcriptional level [61]; this is fully compatible
with a transcriptional regulation of IRS2 by the nuclear JNK3
through regulation of FoxO3A. These data therefore reinforce our
previous hypothesis, that stated that it might be the sub-cellular
localizations of the different JNK isoforms that is predominant in
governing the cellular response: JNK1 and JNK2 may lead to
predominantly cytosolic responses (for example by binding to and
phosphorylating and blocking the IRS proteins), while JNK3 will
impact on nuclear responses (eg c-Jun expression or stability,
transcriptional regulation of IRS2, etc). An important consequence
of these recent works is that the JNK 1 and 2 probably mediate
apoptosis mainly through cytosolic modifications of pre-existing
proteins, while JNK3 appears to have a protective role which is
essentially nuclear (transcriptionally) mediated. These conclusions
might help understanding why previous attempts at characterizing
the transcriptional effectors of apoptosis regulated by JNK were
often disappointing.
In summary, we described here that expression of IRS2 is under
the specific control of JNK3 in insulin-secreting cells. Hence,
JNK3 appears to maintain the IRS2/Akt2 signaling module which
is required to preserve beta-cell function and mass. Microarray
studies using islet cells lacking Jnk3 will establish the panel of genes
that are regulated by JNK3 in pancreatic beta-cells (under
investigation). Some of these genes might reveal new protective
routes used by beta-cells to preserve their mass or function.
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